LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 7,486.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53,864 shares of the medical instruments supplier’s stock after acquiring an additional 53,154 shares during the quarter. GAMMA Investing LLC owned 0.24% of LeMaitre Vascular worth $4,519,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in LMAT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of LeMaitre Vascular by 1.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,737 shares of the medical instruments supplier’s stock valued at $3,293,000 after purchasing an additional 470 shares during the last quarter. Snowden Capital Advisors LLC grew its position in shares of LeMaitre Vascular by 10.8% in the fourth quarter. Snowden Capital Advisors LLC now owns 7,733 shares of the medical instruments supplier’s stock valued at $713,000 after purchasing an additional 751 shares during the last quarter. Nicholas Investment Partners LP grew its position in shares of LeMaitre Vascular by 4.3% in the fourth quarter. Nicholas Investment Partners LP now owns 51,597 shares of the medical instruments supplier’s stock valued at $4,754,000 after purchasing an additional 2,116 shares during the last quarter. Occudo Quantitative Strategies LP grew its position in shares of LeMaitre Vascular by 20.0% in the fourth quarter. Occudo Quantitative Strategies LP now owns 3,413 shares of the medical instruments supplier’s stock valued at $314,000 after purchasing an additional 569 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of LeMaitre Vascular by 96.8% in the fourth quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier’s stock valued at $8,853,000 after purchasing an additional 47,250 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on LMAT shares. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective on the stock. Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $97.83.

Insider Activity at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 18,733 shares of the firm’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the completion of the sale, the chief executive officer now directly owns 1,873,651 shares of the company’s stock, valued at approximately $158,829,395.27. This trade represents a 0.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 100,000 shares of company stock valued at $8,556,857. Corporate insiders own 9.50% of the company’s stock.

LeMaitre Vascular Trading Up 0.4%

Shares of LMAT stock opened at $83.63 on Wednesday. The company’s fifty day simple moving average is $83.68 and its 200-day simple moving average is $90.69. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The company has a market cap of $1.89 billion, a PE ratio of 45.70, a P/E/G ratio of 2.22 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $59.87 million during the quarter, compared to analysts’ expectations of $57.61 million. During the same period in the prior year, the business posted $0.44 EPS. The business’s revenue was up 12.0% on a year-over-year basis. Equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular’s payout ratio is 40.40%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.